In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020 - Liu, Po-Yu; Ko, Wen-Chien; Lee, Wen-Sen; Lu, Po-Liang; Chen, Yen-Hsu; Cheng, Shu-Hsing; Lu, Min-Chi; Lin, Chi-Ying; Wu, Ting-Shu; Yen, Muh-Yong; Wang, Lih-Shinn; Liu, Chang-Pan; et al. (Journal of microbiology, immunology and infection, 2022)
Keywords: Acinetobacter baumannii; Amikacin - pharmacology; Anti-Bacterial Agents - pharmacology; beta-Lactamase Inhibitors - pharmacology; Carbapenems - pharmacology; Cefepime - pharmacology; Cefepime/enmetazobactam; Cefepime/zidebactam; Cefiderocol; Ceftazidime - pharmacology; Cephalosporins - pharmacology; Drug Resistance, Multiple, Bacterial; Eravacycline; Humans; Omadacycline; Pseudomonas aeruginosa; Sepsis; Taiwan; Tazobactam; Tetracyclines - pharmacology; Tigecycline - pharmacology; Taiwan; Eravacycline; Cefepime/zidebactam; Cefepime/enmetazobactam; Cefiderocol; Omadacycline